Successful Treatment of Aluminum Phosphide Poisoning with Continuous Veno-venous Hemofiltration: A Case Report

Ayça Açıkalın1, Nezihat Rana Dişel1, Emre Karakoç2, Selçuk Matyar3, Ahmet Sebe1
1Department of Emergency Medicine, Çukurova University School of Medicine, Adana, Turkey
2Department of Intensive Care, Çukurova University School of Medicine, Adana, Turkey
3Department of Medical Biochemistry, Çukurova University School of Medicine, Adana, Turkey

ABSTRACT
Introduction: We aim to discuss the case of a patient with aluminum phosphide (AP) poisoning in a suicide attempt and who was successfully treated with continuous veno-venous hemofiltration (CVVH).

Case Report: A 24-year old lady was admitted to a hospital with complaints of dizziness, numbness in the face, and nausea and vomiting after taking two tablets of AP. She was transferred to our emergency clinic 10 h later because of persistent hypotension and metabolic acidosis. Her Glasgow Coma Scale score was 13 on admission. Her vital signs were as follows: blood pressure, 80/50 mmHg; pulse rate, 128/min; pulse oximetry, 90%; and respiration rate, 26/min. Her laboratory tests revealed the following: pH, 7.13; bicarbonate level, 10.1 mmol/L; and serum lactate level, 10.2 mmol/L. Other blood test results were normal. CVVH (Prismaflex hemofiltration set M150) was started in the intensive care unit because hypotension and metabolic acidosis were persistent; oliguria was added despite fluid resuscitation and inotrope infusion. Hemofiltration was continued until the 32nd hour when blood pressure and blood gas levels returned to normal. She was discharged healthy on the 4th day of hospitalization.

Conclusion: We suggest the utilization of CVVH in the early stages of AP poisoning before the development of multiple organ failure because AP causes metabolic acidosis and hypotension resistant to medical treatment.

Keywords: Aluminum phosphide, continuous veno-venous hemofiltration, poisoning

Received: 11.11.2015  Accepted: 30.12.2015  Available Online Date: 04.02.2016

Introduction
Aluminum phosphide (AP) is a pesticide that has been used since the 1940s (1). It is a metal phosphide compound (Na₃P, AlP) and is used as a rodenticide and insecticide. AP in an evaporable tablet form is used in wheat storage to reduce the number of mice attacks. This form causes fatalities, in suicidal exposure in particular. In countries such as Turkey, Iran, and India, public awareness of deadly exposure results in oral intake of AP. She was transferred to our emergency clinic 10 h later because of persistent hypotension and metabolic acidosis. The Glasgow Coma Scale score was 13 on admission. Her vital signs were as follows: blood pressure, 80/50 mmHg; pulse rate, 128/min; pulse oximetry, 90%; and respiration rate, 26/min. Her laboratory tests revealed the following: pH, 7.13; bicarbonate level, 10.1 mmol/L; and serum lactate level, 10.2 mmol/L. Other blood test results were normal. CVVH (Prismaflex hemofiltration set M150) was started in the intensive care unit because hypotension and metabolic acidosis were persistent; oliguria was added despite fluid resuscitation and inotrope infusion. Hemofiltration was continued until the 32nd hour when blood pressure and blood gas levels returned to normal. She was discharged healthy on the 4th day of hospitalization.

Case Report
A 24-year old lady was admitted to an urban hospital with complaints of dizziness, numbness in the face, and nausea and vomiting after taking two tablets of AP. Gastric irrigation was performed, and she was given n-acetylcysteine, magnesium sulfate, and nicothine. She was transferred to our emergency clinic 10 h later because of persistent hypotension and metabolic acidosis. Her Glasgow Coma Scale score was 13 on admission. Her vital signs were as follows: blood pressure, 80/50 mmHg; pulse rate, 128/min; pulse oximetry, 90%; and respiration rate, 26/min. Her laboratory tests revealed the following: pH, 7.13; bicarbonate level, 10.1 mmol/L; and serum lactate level, 10.2 mmol/L. Other blood test results were normal. CVVH (Prismaflex hemofiltration set M150) was started in the intensive care unit because hypotension and metabolic acidosis were resistant to medical treatment.

Conclusion: We suggest the utilization of CVVH in the early stages of AP poisoning before the development of multiple organ failure because AP causes metabolic acidosis and hypotension resistant to medical treatment.

Keywords: Aluminum phosphide, continuous veno-venous hemofiltration, poisoning

Received: 11.11.2015  Accepted: 30.12.2015  Available Online Date: 04.02.2016

Herein we aim to discuss the case of a patient with AP poisoning in a suicide attempt and who was successfully treated with continuous veno-venous hemofiltration.

Address for Correspondence:
Ayça Açıkalın, Department of Emergency Medicine, Çukurova University School of Medicine, Adana, Turkey
E-mail: aycaacikalin@yahoo.com
©Copyright 2016 by Emergency Physicians Association of Turkey - Available online at www.jemcr.org
sodium bicarbonate, crystalloids, and inotropes to control hypotension. She was transferred to our emergency clinic 10 h later because of hypotension resistant to medical treatment and persistent metabolic acidosis. She had confusion, and her Glasgow Coma Scale score was 13 on admission. Her vital signs were as follows: blood pressure, 80/50 mmHg; pulse rate, 128/minute; pulse oximetry, 90%; and respiration rate, 26/min. She had pallor; her skin was wet, and the capillary filling time was >2 s.

Her laboratory test results revealed the following: pH, 7.13; bicarbonate level, 10.1 mmol/L; and serum lactate level, 10.2 mmol/L. Other biochemical and hematologic blood test results were within normal ranges. She had already received medical treatment for hypotension and metabolic acidosis and was still under inotrope infusion. Continuous veno-venous hemofiltration (Prismaflex hemofiltration set M150; Baxter, Lund, Sweden) was started in the intensive care unit. Magnesium sulfate at a dose of 4 g/day and inotrope infusion were simultaneously given. Hemofiltration was continued until the 32nd hour when the blood pressure, blood gas levels, and tissue perfusion signs returned to normal. She had no abnormality except anemia after hemofiltration. The vital signs and laboratory results of the patient are summarized in Table 1. She was discharged healthy without any sequela on the 4th day of hospitalization. Written consent of the patient was obtained for preparing this case report.

Discussion

Metal phosphide compounds are widely used as rodenticides and insecticides in Turkey (2). AP is manufactured in the solid form and is stored as packed huge tablets and granules. These tablets turn into the gaseous form in 1 or 2 h following the destruction of the protective package. Poisoning occurs when this gas is inhaled or when tablets are accidentally or intentionally swallowed in a suicide attempt (1).

Intentional oral intake in a suicide attempt is a frequently seen form of exposure of AP, in Iran and India in particular (1). When intentionally ingested, phosphine formed from AP causes hypotension resistant to medical treatment, persistent metabolic acidosis, and MOF by lipid peroxidation due to the inhibition of mitochondrial cytochrome oxidase enzyme and oxygen utilization in cellular basis. There is no antidote of AP, and the mortality rate because of this poisoning is extremely high (1, 4).

The mortality rate of AP poisoning was reported to be as high as 65% in a retrospective study by Singh et al. (5). The study by Moghadamnia et al. (6) in Iran revealed 19 mortalities from 21 AP poisoning patients. The reported mortality rate of AP poisoning in literature is 37–100% (1, 6). This poisoning, which has a high mortality rate, has no specific treatment options. There are reports of particular effective treatment modalities that may reduce mortality rates. Gastric lavage with potassium permanganate is one of these treatment options suggested in early admissions. However, the inhalation and diffusion of phosphine make this decontamination option ineffective for decreasing absorption.

Symptomatic treatment modalities are major management approaches. Death is inevitable in patients with resistant hypotension, metabolic acidosis, and poor tissue perfusion. In this phase, inotropes for resistant hypotension and sodium bicarbonate for metabolic acidosis have been reported in many studies as supportive measures (1). Although it is not an antidote, magnesium is suggested in the treatment of such patients. Magnesium is a cofactor in the synthesis of glutathione and other antioxidants. Hypomagnesemia

### Table 1. The vital signs and laboratory results of the patient

<table>
<thead>
<tr>
<th>Result</th>
<th>Before hemofiltration</th>
<th>After hemofiltration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood pressure (mmHg)</strong></td>
<td>120/60</td>
<td>80/50</td>
</tr>
<tr>
<td><strong>Pulse rate (per minute)</strong></td>
<td>124</td>
<td>128</td>
</tr>
<tr>
<td><strong>Blood pH</strong></td>
<td>7.18</td>
<td>7.13</td>
</tr>
<tr>
<td><strong>HCO3- (mmol/L)</strong></td>
<td>11.1</td>
<td>10.1</td>
</tr>
<tr>
<td><strong>Lactate (mmol/L)</strong></td>
<td>7.5</td>
<td>10.2</td>
</tr>
<tr>
<td><strong>Hemoglobin (g/dL)</strong></td>
<td>12</td>
<td>10.4</td>
</tr>
<tr>
<td><strong>Hematocrit (%)</strong></td>
<td>38.4</td>
<td>32</td>
</tr>
<tr>
<td><strong>BUN (mg/dL)</strong></td>
<td>10</td>
<td>26.1</td>
</tr>
<tr>
<td><strong>Cr (mg/dL)</strong></td>
<td>0.87</td>
<td>1.1</td>
</tr>
</tbody>
</table>

**BUN:** blood urea nitrogen, **Cr:** creatinine, **HCO3:** blood bicarbonate.
is seen after AP poisoning (1). In a study with 50 patients, the mortality rate of patients who received magnesium was 20%, while it was 40% who did not (7).

Our patient had taken two AP tablets in a suicide attempt. She was started on dopamine, magnesium, and sodium bicarbonate infusions. She was admitted to the intensive care unit to perform continuous veno-venous hemofiltration to treat resistant hypotension and metabolic acidosis. This is a method to treat acid-base and electrolyte disorders of hemodynamically unstable patients. In poisoned patients, ongoing metabolic acidosis and hypotension resistant to medical treatment lead to myocardial depression and MOF. There are several reports on the successful utilization of hemofiltration in poisoning cases with hypotension and metabolic acidosis, especially in patients with salicylate and metformin overdoses (8). There is a case report of a patient who underwent continuous veno-venous hemofiltration for AP poisoning. Unfortunately, this patient died because of ventricular tachycardia unresponsive to cardioversion (9). Nasa et al. (10) reported two patients with acute AP poisoning who survived after continuous renal replacement therapy. We started hemofiltration before MOF occurred in our patient. Long periods of metabolic acidosis and hypotension cause a high mortality rate due to irreversible cardiac problems and additive MOF. We started hemofiltration as soon as resistant hypotension and metabolic acidosis were diagnosed and the serum creatinine level was 1.1 mg/dL. The patient was under continuous veno-venous hemofiltration for 32 h. No laboratory abnormality and complication were detected. She was discharged healthy on the 4th day of hospitalization.

Conclusion
We suggest hemofiltration in the early stages of clinical follow-up as a treatment choice in poisoning patients, particularly if the agent causes metabolic acidosis and resistant hypotension. In poisoning with AP, hemofiltration may be a life-saving method as it prevents progression to cardiovascular complications and MOF due to prolonged metabolic acidosis. Further studies are needed to determine the effectiveness of hemofiltration in AP poisoning.

Informed Consent: Written informed consent was obtained from patient who participated in this case.

Peer-review: Externally peer-reviewed.


Conflict of Interest: The authors declared no conflict of interest.

Financial Disclosure: The authors declared that this study has received no financial support.

References
9. Finkle SN. Should dialysis be offered in all cases of metformin-associated lactic acidosis? Crit Care 2009; 13: 110. [CrossRef]